- Home
- MEIP vs KFFB Comparison
MEIP vs KFFB Comparison
Compare MEIP & KFFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- KFFB
- Stock Information
- Founded
- MEIP 2000
- KFFB 2005
- Country
- MEIP United States
- KFFB United States
- Employees
- MEIP N/A
- KFFB N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- KFFB Savings Institutions
- Sector
- MEIP Health Care
- KFFB Finance
- Exchange
- MEIP Nasdaq
- KFFB Nasdaq
- Market Cap
- MEIP 19.5M
- KFFB 20.7M
- IPO Year
- MEIP 2003
- KFFB 2005
- Fundamental
- Price
- MEIP $2.78
- KFFB $2.64
- Analyst Decision
- MEIP Hold
- KFFB
- Analyst Count
- MEIP 2
- KFFB 0
- Target Price
- MEIP $7.00
- KFFB N/A
- AVG Volume (30 Days)
- MEIP 53.1K
- KFFB 10.8K
- Earning Date
- MEIP 11-12-2024
- KFFB 11-12-2024
- Dividend Yield
- MEIP N/A
- KFFB 15.18%
- EPS Growth
- MEIP N/A
- KFFB N/A
- EPS
- MEIP N/A
- KFFB N/A
- Revenue
- MEIP N/A
- KFFB $7,475,000.00
- Revenue This Year
- MEIP N/A
- KFFB N/A
- Revenue Next Year
- MEIP $300.00
- KFFB N/A
- P/E Ratio
- MEIP N/A
- KFFB N/A
- Revenue Growth
- MEIP 33.76
- KFFB N/A
- 52 Week Low
- MEIP $2.61
- KFFB $2.50
- 52 Week High
- MEIP $6.91
- KFFB $5.06
- Technical
- Relative Strength Index (RSI)
- MEIP 36.75
- KFFB 44.39
- Support Level
- MEIP $2.76
- KFFB $2.58
- Resistance Level
- MEIP $2.91
- KFFB $2.78
- Average True Range (ATR)
- MEIP 0.11
- KFFB 0.13
- MACD
- MEIP -0.04
- KFFB 0.01
- Stochastic Oscillator
- MEIP 5.13
- KFFB 34.87
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company through its subsidiaries is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans and types of deposits, etc. The company mainly operates in Perry, Franklin, Boyle and Garrard and surrounding counties in Kentucky, US.